drugset / Trial / NCT00850174

Oxcarbazepine 600 mg Tablets Under Fasting Conditions

NCT00850174

Phase 1 Completed 60 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to evaluate the comparative bioavailability between Oxcarbazepine 600 mg Tablets (test) and Trileptal® 600 mg Tablets (reference) after a single-dose in healthy subjects under fasting conditions.

Timeline

Start
2005-04
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxcarbazepine Small molecule 600 mg

Indications

No indication recorded.